Management tracks: Allogene snags Adaptimmune's Amado; plus Foundation Medicine, CymaBay and more

CAR T therapy company Allogene Therapeutics Inc. (NASDAQ:ALLO) hired Rafael G. Amado as EVP of R&D and CMO, effective Sept. 3. He was president of R&D at Adaptimmune Therapeutics plc (NASDAQ:ADAP). Allogene Executive Chairman and Co-founder Arie Belldegrun previously worked with Amado at UCLA, as did CEO, President and Co-founder David Chang. Adrian Rawcliffe, Adaptimmune's incoming CEO, announced Amado's departure last week.

The Foundation Medicine Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) hired Priti Hegde as CSO. She succeeds Michael Doherty, who will retire in September. Hegde was the senior director and principal scientist in oncology biomarker development at Roche's Genentech Inc. unit...